Status:

COMPLETED

To Yield Further Information On The Efficacy And Safety Of Viagra Among Subjects With Arterial Hypertension .

Lead Sponsor:

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Conditions:

Impotence

Hypertension

Eligibility:

MALE

18+ years

Phase:

PHASE4

Brief Summary

To assess changes with respect to Erectile Dysfunction in subjects treated with Viagra and antihypertensive therapy.

Eligibility Criteria

Inclusion

  • Subjects with arterial hypertension treated with one or more antihypertensive agents, the doses of which have been stable for at least 4 weeks prior to the baseline visit, with a documented clinical diagnosis of ED and a confirmation of this by a qualification of 21 or less on the SHI-M.

Exclusion

  • Subjects with resting sitting systolic blood pressure \>170 or \<110mmHg or resting sitting diastolic blood pressure \>90 or \<50mmHg, with significant cardiovascular disease and retinitis pigmentosa, treatment with nitrates, alfablockers or CYP3A4 inhibitors.

Key Trial Info

Start Date :

March 1 2005

Trial Type :

INTERVENTIONAL

End Date :

November 1 2005

Estimated Enrollment :

253 Patients enrolled

Trial Details

Trial ID

NCT00150358

Start Date

March 1 2005

End Date

November 1 2005

Last Update

February 1 2021

Active Locations (16)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (16 locations)

1

Pfizer Investigational Site

Torreón, Coahuila, Mexico, 72000

2

Pfizer Investigational Site

Guadalajara, Jalisco, Mexico, 44290

3

Pfizer Investigational Site

Colonia Centro, Mexico City, Mexico, 06090

4

Pfizer Investigational Site

DF, Mexico City, Mexico, 06760

To Yield Further Information On The Efficacy And Safety Of Viagra Among Subjects With Arterial Hypertension . | DecenTrialz